Annual report pursuant to Section 13 and 15(d)

CONSOLIDATED STATEMENTS OF OPERATIONS

v3.19.3.a.u2
CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
12 Months Ended
Oct. 31, 2019
Oct. 31, 2018
Revenue $ 250,000 $ 1,112,500
Operating costs and expenses:    
Inventor royalties, contingent legal fees, litigation and licensing expenses 166,250 768,410
Amortization of patents 418,750 325,296
Research and development expenses (including non-cash share based compensation expenses of $2,825,630 and $4,596,866, respectively) 5,473,427 6,813,043
General and administrative expenses (including non-cash share based compensation expenses of $2,888,115 and $4,298,748 respectively) 5,662,828 6,911,830
Impairment in carrying amount of patent assets (Note 2) 418,750 582,979
Total operating costs and expenses 12,140,005 15,401,558
Loss from operations (11,890,005) (14,289,058)
Interest income 71,353 45,974
Loss before income taxes (11,818,652) (14,243,084)
Provision for income taxes (Note 6)
Net loss (11,818,652) (14,243,084)
Less: Net loss attributable to noncontrolling interest (171,598) (247,059)
Net loss attributable to common stockholders $ (11,647,054) $ (13,996,025)
Net loss per share:    
Basic and diluted (in Dollars per share) $ (0.59) $ (0.79)
Weighted average common shares outstanding:    
Basic and diluted (in Shares) 19,789,795 17,624,335